ADAMTS2 knockdown mitigated LPS-induced epithelial injury and barrier dysfunction, in association with PI3K/AKT/mTOR signaling and autophagy-related changes, suggesting ADAMTS2 as a potential therapeutic target for ARDS pending further in vivo validation.
Gao et al. (2026) studied this question.